Needham & Company Reaffirms Buy Rating on VIVUS (VVUS)
VVUS has been the subject of a number of other recent research reports. Analysts at MLV & Co raised their price target on shares of VIVUS from $30.00 to $34.00 in a research note to investors on Monday, April 30th. They now have a “buy” rating on the stock. Separately, analysts at Credit Suisse (NYSE: CS) initiated coverage on shares of VIVUS in a research note to investors on Wednesday, April 25th. They set an “outperform” rating and a $34.00 price target on the stock. Finally, analysts at Bank of America (NYSE: BAC) raised their price target on shares of VIVUS from $26.00 to $30.00 in a research note to investors on Tuesday, April 10th. They now have a “buy” rating on the stock.
Shares of VIVUS traded up 0.18% during mid-day trading on Tuesday, hitting $22.82. VIVUS has a one year low of $6.13 and a one year high of $26.75. The company’s market cap is $2.275 billion.
VIVUS last issued its quarterly earnings data on Monday, May 7th. The company reported ($0.20) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.13) by $0.07. On average, analysts predict that VIVUS will post $-0.20 earnings per share next quarter.
VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in development and commercialization of therapeutic drugs for large underserved markets, including obesity and related morbidities, such as sleep apnea and diabetes and men’s sexual health.